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CASE REPORT 
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Eight patients rechallenged with lamotrigine after initial exposure which resulted in a skin rash are reported. 
On reintroduction of the lamotrigine, six of the patients had no recurrence of the rash. Of the other two 
patients, one had the occurrence of a mild fluctuating and qualitatively different skin rash on rechallenge. The 
other patient had developed a dose-related rash on initial challenge resulting in a dose reduction. The first 
attempt to re-increase the dose resulted in reappearance of the rash which again disappeared on dose re- 
duction. However a further attempt to re-increase the dose did not result in reappearance of a rash. It is 
suggested that patients who experience a rash but good therapeutic response to lamotrigine might be con- 
sidered for re-dosing. 
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INTRODUCTION 
Lamotrigine is a novel and effective 1 anticon- 
vulsant, indicated for add-on therapy 2 which 
has been associated with skin rashes, leading 
to withdrawal, in up to 2% of patients chal- 
lenged 2. 
Skin rash is the commonest adverse reaction 
leading to withdrawal 3 and rechallenge in 
cases of known hypersensitivity is currently 
contraindicated 2. We present eight cases in 




Case 1 is a 28-year-old male with a 17-year 
history of generalized epilepsy. He had up to 30 
atypical absences daily and tonic-clonic seiz- 
ures every alternate day. He took sodium val- 
proate 1000mg b.d. and clobazam 20mg b.d. 
Lamotrigine was introduced at 25 mg b.d. on 
day 1 and increased to 50mg b.d. on day 4. 
From day 2 he had no further seizures but on 
day 11 developed a generalized papular rash 
involving his arms, shoulders and back but not 
mucosae. It was associated with pyrexia, 
nausea, malaise, depression of platelets from 
217 to 160 × 10s/1 and reduction of white cell 
count from 8 to 3.6 × 109/1. Lamotrigine was 
discontinued on day 13 and by day 17 the rash 
was fading and haematological parameters 
normalizing. He was rechallenged 18 months 
later, commencing at 12.5mg daily on day 1, 
25 mg daily on day 6, 25 mg b.d. on day 11 and 
finally 75 mg daily, in divided doses, from day 
25. Follow-up over the succeeding 15 months 
showed no recurrence of rash or other adverse 
reaction. He was seizure-free from day 1 of 
rechallenge. 
Case 2 
Case 2 is 14-year-old female with 13-year 
history of localization-related pilepsy. She 
was experiencing about six seizures per week 
and took carbamazepine 600mg daily. There 
was a history of sodium valproate idiosyncracy. 
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Lamotrigine was introduced at 100mg daily 
and increased to 200mg daily 2 weeks later. 
Eleven days after the dose increment she de- 
veloped a rash over her face and eyelids. It was 
noted that the rash was worse just after taking 
the tablets in the morning and then improved 
as the day progressed. Lamotrigine was 
stopped 2 days later and the rash resolved. She 
was rechallenged 20 months later with 12.5 mg 
daily, increased to 25 mg daily after 2 weeks 
and then doubled at bi-monthly intervals until 
she was on 200 mg daily. There was no recur- 
rence of rash but rechallenge was therapeuti- 
cally ineffective and lamotrigine was with- 
drawn 1 year later. 
Case 3 
Case 3 is a 9-year-old female with 3-year 
history of localization-related pilepsy and ex- 
periencing three to four seizures daily. She was 
on no medication having previously been tried 
with ethosuximide, carbamazepine and sodium 
valproate without effect. Phenytoin, although 
therapeutically effective, on challenge and 
rechallenge had casued a widespread itchy 
macular ash. 
Lamotrigine was introduced at 12.5mg 
every alternate day but had to be withdrawn 
after 10 days because of development of an 
itchy rash on the inside of her thighs. Rash was 
unassociated with any haematological disturb- 
ance. 
She was rechallenged 2 months later at an 
initial dose of 0.5mg every alternate day, 
which was slowly built up over 6 months to 
12.5 mg daily. The dose was then more quickly 
increased to 75 mg daily over the following 4 
months. There was no recurrence of rash and 
seizure frequency reduced to less than one a 
day. 
Case 4 
Case 4 is an ll-year-old male with 9-year 
history of symptomatic localization-related 
epilepsy. Seizures were uncontrolled on sodium 
valproate 1800 mg daily. He had a history of 
phenytoin-induced rash. Lamotrigine was 
introduced at 25 mg daily and 12 days later he 
developed an itchy maculo-papular rash over 
the inner aspect of both thighs. Lamotrigine 
was stopped immediately, the rash disap- 
peared and the patient recovered completely. 
Lamotrigine was reintroduced 2 years 11 
months later at 12.5 mg on alternate days. The 
dose was gradually built up, over 6 months, 
with him obtaining excellent seizure control on 
100 mg lamotrigine and 2000 mg sodium val- 
proate daily without reapparance ofthe rash. 
Case 5 
Case 5 is a 23-year-old female with 20-year 
history of symptomatic generalized epilepsy. 
On sodium valproate 1000mg daily she was 
experiencing about two drop attacks daily and 
tonic-clonics daily. Lamotrigine was intro- 
duced at 25 mg b.d. with an initial significant 
reduction in seizure frequency. After 3 weeks 
the dose was increased from 150 mg to 200 mg 
daily and 2 days later she developed a vesicu- 
lar and erythematous rash on her hands and 
legs with buccal ulceration but no genital ul- 
ceration. Full blood count was normal. Lamo- 
trigine was discontinued. The rash worsened 
before completely fading by the ninth day. 
Lamotrigine was reintroduced at 25 mg daily 
dose, as an in-patient, 2 years later and the 
dose gradually increased over 4 weeks to 
150 mg daily. There was no recurrence of the 
rash or mucosal ulceration and seizure fre- 
quency was significantly improved. Over the 
following 30 months of follow-up seizure im- 
provement has been maintained with at most 
10-15 drop attacks monthly and no further 
tonic-clonic seizures. However a mild fluctuat- 
ing macular ash has been noted on and under 
her breasts, on her upper thighs, intrascapu- 
larly and over the outer ear canal and abdomi- 
nal wall. This has not been associated with any 
haematological abnormality and never con- 
sidered severe enough to warrant discontinu- 
ation of lamotrigine. 
Case 6 
Case 6 is a 49-year-old lady with 36-year 
history of localization-related pilepsy. Lamo- 
trigine had been stopped due to a mild rash 
before admission to our practice and the nature 
of the rash and concomitant medication are not 
known to us. After admission, lamotrigine was 
reintroduced at 25 mg daily into her concomi- 
tant sodium valproate 1000 mg b.d. treatment. 
She was later discharged to her Primary Care 
Physician (General Practitioner, GP) with the 
same treatment. Her GP was informed to esca- 
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late the daily dose by 25 mg every 2 weeks to a 
maximum dose of 200 mg daily but to discon- 
tinue the lamotrigine if she developed a rash. 
Six months later, her dose was successfuly in- 
creased to 75 mg b.d. without reappearance of
the rash. Her seizure control had been good 
since restarting lamotrigine and the GP has 
not considered it necessary to increase the dose 
to 200 mg. 
Case 7 
Case 7 is a 6-year-old boy with 5.5 year history 
of symptomatic localization-related epilepsy. 
When he was in another hospital, lamotrigine 
was added to his treatment. Although the 
initial dose and concomitant medication are 
not known to us, within 10 days the dose had 
escalated to 100 mg b.d. and he had developed a 
morbilliform rash, lethargy, malaise and 
minor status. All drugs were stopped and he 
recovered. Fifteen months later, he was admit- 
ted to our practice and lamotrigine was rein- 
troduced at 12.5 mg daily as monotherapy. The 
dose was gradually built up to 50 mg b.d. and 
he was discharged to his own GP. His GP suc- 
cessfully increased his dose to 100mg b.d. 
without reappearance ofa rash. 
Case 8 
Case 8 is an 8-year-old boy with 5-year history 
of symptomatic localization-related epilepsy. 
His seizures were not controlled by clonazepam 
3mg and sodium valproate 800mg daily. 
Lamotrigine was added to his treatment at the 
dose of 12.5 mg daily. He tolerated lamotrigine 
very well without any problems: Over the 
following 4 months the dose was gradually in- 
creased to 150 mg daily and sodium valproate 
was reduced and discontinued. Seven months 
later he developed a rash. It was suspected to 
be caused by lamotrigine and therefore lamo- 
trigine was reduced from 150mg to 100mg. 
The rash then disappeared. Ten months later 
the dose of lamotrigine was increased to 
125mg and the rash reappeared. Once again 
lamotrigine was reduced to 100mg and the 
rash disappeared. Four months later the dose 
was increased to 125mg again without the 
reappearance of the rash. The dose was then 
further increased to 250mg daily over the 
following 4 months without adverse ffect. 
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DISCUSSION 
Although there is no experimental evidence 
that any rash was due to lamotrigine, we are 
unable to find alternative xplanations in five 
cases. Two cases (cases 6 and 7) happened out- 
side our practice and so we are unable to 
comment. It is possible that case 1 might be 
due to a concurrent viral infection. 
All but two cases (case 8 and case 6) have 
shown a very good temporal relationship be- 
tween development ofthe rash and lamotrigine 
administration, with the rash developing 
within a short period (<10 to 25 days) of 
lamotrigine administration and all patients re- 
covering after drug withdrawal. These charac- 
teristics are very similar to those reported in 
other literature 2.
Drug-induced rash is normally regarded as a 
Type B reaction in that it cannot be predicted 
by the pharmacological ction, and is normally 
not dose-dependent 4. However, it is recognized 
that a slower rate of introduction of lamotri- 
gine decreases the likelihood of occurrence of 
skin rash 5 as has also been reported for pheny- 
toin and carbamazepine s. Furthermore, cases 2 
and 8 suggest the lamotrigine-related rash was 
dose or concentration-related. 
Dollery has suggested that skin rashes attri- 
buted to lamotrigine hypersensitivity might 
simply be due to misinterpretation f an initial 
coincidental skin rash 7. Although we are not 
able to refute or support Dollery's suggestion, 
it seems unlikely that all reported successful 
rechallenging cases are due to misinterpret- 
ation of the initial skin rash. 
As can be seen from Tables 1 and 2 initial 
introduction and rate of increase in cases 1, 2 
and 5 would be considered high by current cri- 
teria 2. Case 4, with introduction at 25mg 
daily, was also above current guidelines in 
view of concomitant sodium valproate, but 
interestingly reintroduction at 25 mg daily in 
cases 5 and 6, also with concurrent sodium val- 
proate, did not result in rash. 
Initial rechallenge was above current guide- 
lines for initial challenge for cases 5 and 6, 
within for case 1 and below for cases 2 and 4. 
Case 3 was particularly low as instead of a 
planned dose of 5 mg daily, 0.5 mg was admin- 
istered instead. 
The final dose reached varied below 75 mg to 
200 mg total daily dose. In four cases (cases 2, 
3, 4 and 7) the final dose equalled or exceeded 
the dose at which the rash had initially 
appeared. Additionally in case 8 the final dose 
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Table 1 : Summary of cases 1 to 7 
S.J .  Tavernor  et aL 
Initial challenge Rechallenge 
Case Concomitant Dose Dose Time to Time to Delay before Concomitant 
sodium (daily} {daily} develop develop rechallenge sodium 
valproate initial final rash rash (months} valproate 
medication {days} {days} medication 
from from 
intro last dose 
inc. 
Dose Dose Time to 
initial final final 
dose 
1 Yes 50mg 100mg 10 7 18 Yes 12.5 mg 75mg 24 days 
2 No 100mg 200mg 25 11 20 No 12.5 mg 200mg 8 mths 
3 No 12.5 mg 12.5 mg <10 <10 2 No 0.5 mg 75 mg 10 mths 
Alt days Alt days AIt days 
4 Yes 25 mg 25 mg 12 12 35 Yes 12.5 mg 10 mg 6 mths 
Alt days 
5 Yes 50 mg 200 mg 23 2 24 Yes 25 mg 150 mg 4 wks 
6 ? ? ~ ~ ? ? Yes 25 mg 150 mg 6 mths 
7 ~ ? 200 mg 10 ~ 15 No 12.5 mg 200mg ? mths 
Table 2: Summary of case 8 
Initial challenge 
Concomitant sodium Dose Dose Time to develop Time to develop Dose adjustment 
valproate medication (daily} (daily} rash-- f rom intro rash-- f rom last (daily} 
initial final dose increment 
Yes {initial 4 months} 12.5 mg 150 mg 11 months 7 months Reduced to 100 mg 
First increment 
Time since initial rash Concomitant sodium valproate Dose increme.nt (daily} Dose adjustment (daily} 
medication following rash 
10 months No To 125 mg To 100 mg 
Second increment 
Time since initial Time since Concomitant Dose increment Dose increment Time to final dose 
rash second rash sodium valproate - - in i t ia l  -- f inal 
medication 
14 months 4 months No 125 mg 250 mg 4 months 
also exceeded that at which the rashes had 
initially appeared. 
Other clinics than ours have also attempted 
to reintroduce lamotrigine to patients with a 
previous history of lamotrigine-induced rash. 
Schlumberger reintroduced lamotrigine to five 
children after the rash had disappeared s. In 
one child sodium valproate co-medication was 
maintained and the rash recurred 12 hours 
later. In the other four children lamotrigine 
was reintroduced after sodium valproate was 
discontinued and rechallenge was successful. 
Interestingly, in four of the eight cases we 
report lamotrigine was successfully reintro- 
duced with concomitant sodium valproate. 
The experiences from our practice and other 
centres s have demonstrated that it is possible 
to reintroduce lamotrigine to patients with a 
previous history of lamotrigine-related rash. 
However, clinicians have to balance the benefit 
and the risk, especially in the case of serious 
skin reactions such as Steven-Johnson syn- 
drome and therefore we would recommend that 
reintroduction of lamotrigine should be done 
under close supervision. 
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